New combo therapy targets Hard-to-Treat liver cancer
NCT ID NCT05546879
First seen Feb 11, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This early-stage study tests whether adding an experimental drug called NP137 to the standard two-drug therapy (Atezolizumab and Bevacizumab) can improve outcomes for people with advanced liver cancer that cannot be removed by surgery. About 43 adults with unresectable hepatocellular carcinoma will receive the combination as their first treatment. The main goal is to check safety and side effects, while also looking at tumor shrinkage and survival rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de GRENOBLE ALPES
Grenoble, Alpes, 38043, France
Conditions
Explore the condition pages connected to this study.